 SOUTH PLAINFIELD, N.J., Feb. 24, 2021 PRNewswire -- PTC Therapeutics, Inc. NASDAQ: PTCT, today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH study evaluating EvrysdiTM risdiplam in infants with symptomatic type 1 spinal muscular atrophy... 